Cell Medica receives funds for its cell therapy
A USD 8.7 million grant to Cell Medica has been given by Cancer Prevention and Research Institute of Texas (CPRIT) to speed up the clinical development of CMD-502 off-the-shelf chimeric antigen receptor-natural killer T cell (CAR-NKT) cell therapy. The program, supported by Baylor College of Medicine (BCM), aims to offer a simplified manufacturing way to be able to treat a large number of patients.
Blackstone Life Sciences
invests USD 250 million along with Novartis forms a new Biotech Anthos
Anthos Therapeutics, a new leaf in the branch, backed up with USD 250 million to extend the advancement of MAA868, a NO...
